[HTML][HTML] A perspective on anti-EGFR therapies targeting triple-negative breast cancer
K Nakai, MC Hung, H Yamaguchi - American journal of cancer …, 2016 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15 …
receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15 …
Targeted therapies for triple-negative breast cancer: combating a stubborn disease
Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast
cancers that have a poor clinical outcome. Although no approved targeted therapy is …
cancers that have a poor clinical outcome. Although no approved targeted therapy is …
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer
Lipids, either endogenously synthesized or exogenous, have been linked to human cancer.
Here we found that PML is frequently co-deleted with PTEN in metastatic human prostate …
Here we found that PML is frequently co-deleted with PTEN in metastatic human prostate …
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity
Breast cancer is the most frequent cancer in women and consists of heterogeneous types of
tumours that are classified into different histological and molecular subtypes,. PIK3CA and …
tumours that are classified into different histological and molecular subtypes,. PIK3CA and …
RAS-mediated oncogenic signaling pathways in human malignancies
Abnormally activated RAS proteins are the main oncogenic driver that governs the
functioning of major signaling pathways involved in the initiation and development of human …
functioning of major signaling pathways involved in the initiation and development of human …
[HTML][HTML] EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer
X Liu, V Adorno-Cruz, YF Chang, Y Jia… - Theranostics, 2021 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is one of the most aggressive and metastatic breast
cancer subtypes lacking targeted therapy. Our recent work demonstrated that circulating …
cancer subtypes lacking targeted therapy. Our recent work demonstrated that circulating …
[HTML][HTML] Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer
JM Giltnane, JM Balko - Discovery medicine, 2014 - discoverymedicine.com
" Triple negative" breast cancer (TNBC) is the most aggressive and least common clinical
subtype of breast cancer. As its nomenclature implies, TNBC lacks specific biomarker …
subtype of breast cancer. As its nomenclature implies, TNBC lacks specific biomarker …
Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor
Y Liu, Y Zhou, KH Huang, X Fang, Y Li… - Cell …, 2020 - Wiley Online Library
Objectives Traditional cancer therapy and regular immunotherapy are ineffective for treating
triple‐negative breast cancer (TNBC) patients. Recently, chimeric antigen receptor …
triple‐negative breast cancer (TNBC) patients. Recently, chimeric antigen receptor …
The predictive and prognostic role of RAS–RAF–MEK–ERK pathway alterations in breast cancer: revision of the literature and comparison with the analysis of cancer …
Simple Summary The RAS/RAF/MEK/ERK pathway is implicated in fundamental processes
frequently altered in tumors, such as cell proliferation and survival. In breast cancer, it is …
frequently altered in tumors, such as cell proliferation and survival. In breast cancer, it is …
[HTML][HTML] MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma
Therapeutic applications of microRNAs (miRNAs) in RAS-driven glioma were valuable, but
their specific roles and functions have yet to be fully elucidated. Here, we firstly report that …
their specific roles and functions have yet to be fully elucidated. Here, we firstly report that …